Berlin - Delayed Quote • EUR MedMira Inc (47M.BE) Follow 0.0535 0.0000 (0.00%) As of April 25 at 8:48 PM GMT+2. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for 47M.BE 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: 47M.BE View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations MedMira Second Quarter 2024 Earnings: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2023) MedMira Reports Second Quarter Results FY2024 MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira's Products Corporate Update on Clinical Evaluation of MedMira’s Products MedMira Reports First Quarter Results FY2024 U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test MedMira Reports FY2023 Fourth Quarter and Year End Financial Results Update on MedMira’s Regulatory Path in Canada and the USA Progress Update on Securities TSX Venture Exchange Stock Maintenance Bulletins MedMira Reports Third Quarter Results FY2023
